<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00546702</url>
  </required_header>
  <id_info>
    <org_study_id>HMR1964A_3505</org_study_id>
    <nct_id>NCT00546702</nct_id>
  </id_info>
  <brief_title>Glulisine + Lantus in Type I Patients</brief_title>
  <official_title>Multicenter, Open, Non-Randomised Phase III Clinical Study of Efficacy and Safety of Insulin Glulisine (HMR1964) Injected Subcutaneously in Patients With Type 1 Diabetes Mellitus Using Also Insulin Glargine During 26 Weeks of Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy (in terms of change HbA1c from baseline to endpoint) and safety (in
      terms of adverse events, clinical chemistry, lipids, hematology) of insulin glulisine (HMR
      1964) in subjects with type I diabetes mellitus To evaluate the change in HbA1c at week 26,
      blood/glucose parameters, hypoglycemia, insulin dose in subjects with type I diabetes
      mellitus receiving HMR 1964 and insulin glargine.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2004</start_date>
  <completion_date type="Actual">February 2005</completion_date>
  <primary_completion_date type="Actual">February 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change of HbA1c.</measure>
    <time_frame>from baseline to endpoint.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in HbA1c.</measure>
    <time_frame>from baseline (week 1) to weeks 12 and 26</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood glucose parameters, hypoglycaemic episodes and dosage of the mealtime and basal insulins.</measure>
    <time_frame>from baseline to endpoint.</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">142</enrollment>
  <condition>Diabetes Mellitus, Type 1</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Insuline Glulisine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult men and women (&gt;18 years) with type I diabetes mellitus (onset of diabetes under
             the age of 40)

          -  An HbA1c range of &gt;6.5 - &lt;11%

          -  And on multiple injection regimen (more than 1 year of continuous insulin treatment)

          -  Body mass index &lt;35.

        Exclusion Criteria:

          -  Active proliferative diabetic retinopathy

          -  Diabetes other than type I diabetes mellitus

          -  Pancreatectomised subjects

          -  Subjects who have undergone pancreas and or islet cell transplantats, requiring
             treatment with not permited drugs during the study, previous treatment (in the period
             not less than 1 month before the beginning of the trial) with insulin glargine

          -  Hypersensitivity to insulin

          -  Major systemic diseases

          -  Impaired hepatic or renal function

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Olga Efremenkova</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Sanofi-aventis</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 18, 2007</study_first_submitted>
  <study_first_submitted_qc>October 18, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 19, 2007</study_first_posted>
  <last_update_submitted>June 12, 2009</last_update_submitted>
  <last_update_submitted_qc>June 12, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 15, 2009</last_update_posted>
  <responsible_party>
    <name_title>Medical Affairs Study Director</name_title>
    <organization>sanofi-aventis</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

